C3PO: Predicting tuberculosis recurrence with blood and sputum tests

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

C3PO is an observational supplement within the R2D2 TB Network that follows people who completed the 6-month HRZE regimen to look for markers that predict TB coming back. The study collects sputum and blood samples to measure non-culture pharmacodynamic markers such as the RS ratio and host immune-response assays and links those measurements to later recurrence under routine programmatic care. By comparing these biomarkers to clinical outcomes, the study aims to find faster, more accurate predictors of relapse than sputum culture. The work is conducted across multiple outpatient sites in Uganda and Vietnam with academic and federal collaborators.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. . individuals age ≥ 12 years;
2. . have completed treatment for drug-susceptible tuberculosis with the standard 6-month regimen of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE).

Exclusion Criteria:

1. completed treatment for drug-susceptible tuberculosis \>14 days prior to screening/enrollment;
2. routinely taking any medication with anti-mycobacterial activity (including fluoroquinolones) for any reason not related to tuberculosis treatment within the last 14 days;
3. unwilling to provide informed consent or return for study follow-up visits.

Where it's running

• Kisenyi Health Center
  Kampala, Uganda Recruiting
• Mulago Outpatient Department
  Kampala, Uganda Recruiting
• Hanoi Lung Hospital, Outpatient departments
  Hanoi, Vietnam Not yet recruiting

Study contacts

• Principal investigator: Adithya Cattamanchi, MD — University of California San Francisco; University of California Irvine
• Study coordinator: Adithya Cattamanchi, MD
• Email: adithya.cattamanchi@ucsf.edu
• Phone: 415-206-5489

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Doxycycline added to standard treatment for central nervous system tuberculosis

  This trial tests whether adding doxycycline to standard anti‑TB therapy and corticosteroids helps adults with central nervous system tuberculosis live longer or have less severe neurological disability.

  Recruiting at 5 sites Phase 2 National University Hospital, Singapore · Medan, Medan and 5 other locations · NCT06446245

• Biomarker Test for Diagnosis and Monitoring of Extrapulmonary Tuberculosis

  This study tests biomarker-based methods to help diagnose extrapulmonary TB and monitor treatment in adults, including people living with HIV, using samples from affected sites in Kenya.

  Recruiting at 2 sites Nagasaki University · Nairobi and 1 other locations · NCT07901387

• Short-Course TB Treatment for Children with Non-Severe Pulmonary TB

  This trial tests two shorter-treatment options for kids with non-severe pulmonary TB to see if they can clear the infection as well as the standard 6-month plan.

  Recruiting at 13 sites Phase 2 Huashan Hospital · Fuzhou, Fujian and 12 other locations · NCT07893444

• Combined oral contraceptive timing with Ganfeborole in healthy women

  This study tests how the contraceptive Microgynon behaves in the body when given alone and with Ganfeborole in healthy women who can’t get pregnant.

  Recruiting Phase 1 GlaxoSmithKline · Madrid · NCT07784894

• Isoniazid inhalation in TB patients: a first-in-human look at local tolerability and body levels

  This early study tests inhaled isoniazid to see how well it tolerates the lungs and how it behaves in the body in adults with tuberculosis.

  Recruiting Phase 1 University Medical Center Groningen · Groningen · NCT07708779

• How the immune system responds to mycobacterial infections

  This study tests how the immune system changes in people with tuberculosis and related mycobacterial infections.

  Recruiting First Affiliated Hospital of Ningbo University · Ningbo · NCT07638670

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.